Across TCGA pan-cancer cohorts, LINC02662 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of LINC02662’s most consistent transcriptional readouts.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where LINC02662 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC02662 is over-expressed in tumor.
BLCA and PRAD are the cancer types where LINC02662 tumor–normal differential expression is most reproducible.